Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Metabolism. 2000 Aug;49(8):1030-5. doi: 10.1053/meta.2000.7738.
It has been reported that advanced glycosylation end products (AGEs) play an important role in the development of diabetic complications. To evaluate the relationship between serum AGEs and diabetic nephropathy, we measured serum AGE levels in diabetic patients with normoalbuminuria (N), microalbuminuria (M), overt proteinuria (O), and hemodialysis (HD), non diabetic patients with nephropathy, and age-matched control subjects using the enzyme-linked immunosorbent assay (ELISA). Urine AGE levels were also measured in these subjects except group HD. Serum AGE levels in diabetic patients were not significantly higher than those in the normal subjects. When we compared serum AGE levels among various stages of diabetic nephropathy, groups O and HD had significantly higher serum AGE levels than the other groups. Serum AGE levels in group HD were almost 6-fold higher than those in groups N and M. In contrast, there were no significant differences in urinary AGE levels among any diabetic groups. As for the variables that determine serum AGE levels in diabetic patients, there was no significant correlation between serum AGEs and fasting blood glucose, hemoglobin A1c (HbA1c), or duration of diabetes. In contrast, serum AGEs showed a strong correlation with serum creatinine and an inverse correlation with creatinine clearance. To evaluate the relationship between serum AGEs and oxidative stress in diabetic nephropathy, urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and serum malondialdehyde (MDA), which are biological markers of total oxidative stress in vivo, were also examined. Both urinary 8-OHdG and serum MDA levels were significantly higher in diabetic patients with proteinuria versus those without proteinuria. However, there was no significant correlation between serum AGEs and urinary 8-OHdG or serum MDA levels in diabetic patients. These results suggest that the accumulation of serum AGEs in diabetic nephropathy may be mainly due to decreased removal in the kidney rather than increased production by high glucose levels or oxidative stress.
据报道,晚期糖基化终末产物(AGEs)在糖尿病并发症的发生发展中起重要作用。为评估血清AGEs与糖尿病肾病之间的关系,我们采用酶联免疫吸附测定法(ELISA),对正常白蛋白尿(N)、微量白蛋白尿(M)、显性蛋白尿(O)和血液透析(HD)的糖尿病患者、患有肾病的非糖尿病患者以及年龄匹配的对照受试者的血清AGE水平进行了测定。除HD组外,还对这些受试者的尿AGE水平进行了测定。糖尿病患者的血清AGE水平并不显著高于正常受试者。当我们比较糖尿病肾病各阶段的血清AGE水平时,O组和HD组的血清AGE水平显著高于其他组。HD组的血清AGE水平几乎是N组和M组的6倍。相比之下,各糖尿病组之间的尿AGE水平没有显著差异。至于决定糖尿病患者血清AGE水平的变量,血清AGEs与空腹血糖、糖化血红蛋白(HbA1c)或糖尿病病程之间没有显著相关性。相反,血清AGEs与血清肌酐呈强相关,与肌酐清除率呈负相关。为评估血清AGEs与糖尿病肾病氧化应激之间的关系,还检测了作为体内总氧化应激生物标志物的尿8-羟基-2'-脱氧鸟苷(8-OHdG)和血清丙二醛(MDA)。有蛋白尿的糖尿病患者的尿8-OHdG和血清MDA水平均显著高于无蛋白尿的患者。然而,糖尿病患者的血清AGEs与尿8-OHdG或血清MDA水平之间没有显著相关性。这些结果表明,糖尿病肾病中血清AGEs的积累可能主要是由于肾脏清除减少,而非高血糖水平或氧化应激导致的生成增加。